If you have been reading about immunomodulatory peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-12. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Clown loaches are particularly susceptible to Ichthyophthirius (ich), or white spot disease. Due to the fact that clown loaches have small or no scales, they are often not treated with full doses of medications. Over-exploitation of C. macracanthus has motivated the development of conservation efforts, mostly new artificial propagation techniques. C. macracanthus is easier to breed when individuals are between two and four centimeters in size. In the wild, adults feed on worms, crustaceans and plant matter. Most clown loaches accept commercial flake food and sinking pellets as their dietary staple, but thrive with a variety of food: live (worms, brine shrimp, small snails), banana, other plant matter, freeze-dried (tubifex worms, especially if it is fortified) and frozen brine shrimp. Clown loaches (and their cousins) are also one of the few fishes that will eat bladder snails (Physella acuta), and are valued by aquarists for controlling this pest in planted aquaria.
== Generation of the TCR diversity == The generation of TCR diversity is similar to that for antibodies and B-cell antigen receptors. It arises mainly from genetic recombination of the DNA-encoded segments in individual somatic T cells by somatic V(D)J recombination using RAG1 and RAG2 recombinases. Unlike immunoglobulins, however, TCR genes do not undergo somatic hypermutation, and T cells do not express activation-induced cytidine deaminase (AID). The recombination process that creates diversity in BCR (antibodies) and TCR is unique to lymphocytes (T and B cells) during the early stages of their development in primary lymphoid organs (thymus for T cells, bone marrow for B cells). Each recombined TCR possess unique antigen specificity, determined by the structure of the antigen-binding site formed by the α and β chains in case of αβ T cells or γ and δ chains on case of γδ T cells.
=== Glutamate transport === Citicoline lowers increased glutamate concentrations and raises decreased ATP concentrations induced by ischemia. Citicoline also increases glutamate uptake by increasing expression of EAAT2, a glutamate transporter, in vitro in rat astrocytes. It is suggested that the neuroprotective effects of citicoline after a stroke are due in part to citicoline's ability to decrease levels of glutamate in the brain. This is in part due to an indirect decrease in the extrasynaptic NMDA-TRMP4 death signaling pathway. It's important to also note it is only the extrasynaptic NMDA receptors responsible for excitotoxicity.
== Uses == Synthetic platelets have diverse therapeutic applications, including treating hemostasis in trauma care, clotting disorders, and immune responses in conditions such as thrombosis, inflammation, and cancer. Originally researched to replicate the biochemistry and cell and molecular biology of natural platelets, platelet-mimicking particles are now in preclinical development for multiple therapeutic applications with specialized drug delivery mechanisms. The need for these particles is informed by increasing rates of reported thrombocytopenia cases and clinical bleeding syndrome diagnoses such as von Willebrand disease or Glanzmann thrombasthenia. Early treatment solutions of the mid-late twentieth century were not based upon current findings in nanoparticle drug delivery technologies, thus lacking the ability to overcome primary limitations of natural platelets. With a diverse assortment of platelet-mimicking particle formulations under testing, their use can be widespread to multiple clinical diagnoses and areas—antimicrobial platelets, cancer, hemorrhage and trauma, bleeding disorders, and cholesterol clearance.
Sources: en.wikipedia.org
== History == On August 10, 1863, the Napa Valley Register first published. It was founded by J.I. Horrell as a pro-Union paper, in contrast to the pro-Succession Napa Echo. By 1864, the newspaper had dropped “Valley” from its name, becoming simply the Napa Register, until returning to the original name over a century later. Editor R.T. Montgomery retired from the paper in January 1866. He returned that May and sold it to N.E. White in January 1868. White left after six months and Montgomery returned again, only to later sell the Register a second time in November 1869 to R.D. Hopkins, formerly editor of the Vallejo Recorder. Hopkins sold to Rev. George W. Henning and George M. Francis in February 1872. The Register moved to daily publication in December 1872. Henning sold out to Charles A. Gardner in May 1873. Gardner left after a few years to run the St. Helena Star. George M. Francis became sole owner of the Register in 1878, upon the death of his business partner. Francis was succeeded in ownership by his son George H. Francis in 1932. The paper remained with Francis and various partners until 1958, when it was sold to Scripps League Newspapers. Scripps was acquired by Pulitzer in 1996, and Pulitzer was acquired by Lee Enterprises in 2005. Dan Evans became the paper's editor in March 2022, and he soon unveiled a newly reconstituted editorial board that October. The board was made up of three members of the newspaper's staff and seven community members. It aimed to assist in driving the official opinion of the paper. In April 2023, the paper laid off two employees.
He capped off his excellent clay court season by reaching his first major quarterfinal at the French Open. He needed to win three five-set matches to get that far before Thiem ended his run while he was faced with a hamstring injury. Up until the year-end championships, Zverev struggled to build on his early season success. He lost in the third round at both Wimbledon and the US Open, and his best result at the four remaining Masters events was a semifinal at the Shanghai Masters. He was able to defend his title at the Washington Open, his only title during this period. Zverev also reached two more doubles finals with his brother, but did not win either of them. At the end of the season, Zverev qualified for both the Next Generation Finals and the ATP Finals for the second consecutive year, again choosing to only compete at the latter event. He was placed in a group with Novak Djokovic, Marin Čilić, and John Isner. This year, Zverev was able to advance out of the group, only losing to No. 1 Djokovic in the round robin. He faced Federer in the semifinals and defeated him in straight sets to set up a rematch with Djokovic. Despite being a heavy underdog and having just lost to Djokovic earlier in the week, Zverev won the final in straight sets for the tenth and biggest title of his career. He became the youngest tour champion since Djokovic a decade earlier and the first German to win the season-ending championships since Boris Becker in 1995. This was also Zverev's first victory over a current world No. 1 player.
Over the shah's indifference, Domantovich and his Cossacks worked hard on training the Cossack Brigade, which became the only disciplined unit in the entire Persian Army, and thus of considerable importance in maintaining the shah's authority.
Glutathione S-transferase theta-2 is an enzyme that in humans is encoded by the GSTT2 gene. Glutathione S-transferase (GSTs) theta 2 (GSTT2) is a member of a superfamily of proteins that catalyze the conjugation of reduced glutathione to a variety of electrophilic and hydrophobic compounds. Human GSTs can be divided into five main classes: Alpha, Mu, Pi, Theta, and Zeta. The theta class members GSTT1 and GSTT2 share 55% amino acid sequence identity and both are thought to have an important role in human carcinogenesis. The theta genes have a similar structure, being composed of five exons with identical exon/intron boundaries.
== Success rate == Candidates for a new drug to treat a disease might, theoretically, include from 5,000 to 10,000 chemical compounds. On average about 250 of these show sufficient promise for further evaluation using laboratory tests, mice and other test animals. Typically, about ten of these qualify for tests on humans. A study conducted by the Tufts Center for the Study of Drug Development covering the 1980s and 1990s found that only 21.5 percent of drugs that started Phase I trials were eventually approved for marketing. In the time period of 2006 to 2015, the success rate was 9.6%. The high failure rates associated with pharmaceutical development are referred to as the "attrition rate" problem. Careful decision making during drug development is essential to avoid costly failures. In many cases, intelligent programme and clinical trial design can prevent false negative results. Well-designed, dose-finding studies and comparisons against both a placebo and a gold-standard treatment arm play a major role in achieving reliable data.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.